Literature DB >> 12001076

Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection.

Russell W Hinerman1, William M Mendenhall, Robert J Amdur, Scott P Stringer, Douglas B Villaret, K Thomas Robbins.   

Abstract

PURPOSE: To present the results of radiotherapy with or without neck dissection for squamous cell carcinoma of the supraglottic larynx treated at the University of Florida and to compare these data with those obtained after conservation surgery. METHODS AND MATERIALS: Continuous-course radiotherapy alone or combined with a planned neck dissection was used to treat 274 patients with squamous cell carcinoma of the supraglottic larynx between 1964 and 1998. All patients had follow-up for a minimum of 2 years, and 250 (91%) had follow-up for 5 years or more.
RESULTS: At 5 years, the actuarial probability of local control after radiotherapy according to T stage was as follows: T1, 100%; T2, 86%; T3, 62%; and T4, 62%. The probability of cause-specific survival at 5 years by AJCC stage was as follows: stage I, 100%; II, 93%; III, 81% IVA, 50%; and IVB, 13%. The risk of severe late complications was 4%. Of 57 patients undergoing planned postradiotherapy neck dissection, 7% experienced a severe complication.
CONCLUSIONS: On the basis of our data and the literature, early or moderately advanced supraglottic carcinomas may be treated successfully with either supraglottic laryngectomy or radiotherapy. Supraglottic laryngectomy probably produces a higher initial local control rate but, based on anatomic and coexisting medical constraints, is suitable for a smaller subset of patients and has a higher risk of complications compared with radiotherapy. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12001076     DOI: 10.1002/hed.10069

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  18 in total

1.  Supraglottic laryngectomy: analysis of 267 cases.

Authors:  Maria Agustina Sevilla; Juan Pablo Rodrigo; José Luis Llorente; Rubén Cabanillas; Fernando López; Carlos Suárez
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-08-08       Impact factor: 2.503

2.  When is radiation therapy in head and neck squamous cell carcinoma not indicated?

Authors:  William M Mendenhall; Primož Strojan; Carl E Silver; Randall P Owen; Alessandra Rinaldo; Ashok R Shaha; Avraham Eisbruch; Robert P Takes; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-20       Impact factor: 2.503

3.  Extended and standard supraglottic laryngectomies: a review of 110 patients.

Authors:  Jean-Michel Prades; Pierre-Gilles Simon; Andrei P Timoshenko; Jean-Marc Dumollard; Thierry Schmitt; Christian Martin
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-19       Impact factor: 2.503

4.  When is definitive radiotherapy the preferred treatment for head and neck squamous cell carcinoma?

Authors:  William M Mendenhall; Primož Strojan; Avraham Eisbruch; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-30       Impact factor: 2.503

5.  Glottic and supraglottic pT3 squamous cell carcinoma: outcomes with transoral laser microsurgery.

Authors:  Dimitrios Pantazis; Georgia Liapi; Dimitrios Kostarelos; Georgios Kyriazis; Theodoros-Leonidas Pantazis; Maria Riga
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-29       Impact factor: 2.503

Review 6.  Systematic review and meta-analysis of the use of tranexamic acid in tonsillectomy.

Authors:  Chee Ching Chan; Yee Yin Chan; Faiz Tanweer
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-21       Impact factor: 2.503

7.  Factors predictive of outcome following primary total laryngectomy for advanced squamous cell carcinoma.

Authors:  Thomas F Pezier; Iain J Nixon; Anil Joshi; Teresa Guerrero-Urbano; Richard Oakley; Jean-Pierre Jeannon; Ricard Simo
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-23       Impact factor: 2.503

8.  Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.

Authors:  F Christopher Holsinger; Merrill S Kies; Eduardo M Diaz; Ann M Gillenwater; Jan S Lewin; Lawrence E Ginsberg; Bonnie S Glisson; Adam S Garden; Nebil Ark; Heather Y Lin; J Jack Lee; Adel K El-Naggar; Waun Ki Hong; Dong M Shin; Fadlo R Khuri
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

Review 9.  MicroRNAs in laryngeal cancer: implications for diagnosis, prognosis and therapy.

Authors:  Pei Li; Hui Liu; Zhiyuan Wang; Feng He; Haifeng Wang; Zhi Shi; Ankui Yang; Jin Ye
Journal:  Am J Transl Res       Date:  2016-05-15       Impact factor: 4.060

Review 10.  Causes of death of patients with laryngeal cancer.

Authors:  Alfio Ferlito; Missak Haigentz; Patrick J Bradley; Carlos Suárez; Primož Strojan; Gregory T Wolf; Kerry D Olsen; William M Mendenhall; Vanni Mondin; Juan P Rodrigo; Carsten C Boedeker; Marc Hamoir; Dana M Hartl; Jennifer L Hunt; Kenneth O Devaney; Lester D R Thompson; Alessandra Rinaldo; Robert P Takes
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.